JK184, a cell-permeable imidazopyridine derivative compound, is a potent downstream hedgehog (Hh) signaling antagonist that inhibits Shh-N-mediated Gli-transcription (IC50= 30 nM) and shows suppression of GLI1 and Ptch1 mRNA expression in a dose-dependent manner. JK184 has been found to function by inhibiting class IV alcohol dehydrogenase (Adh7), with an IC50 of 210 nM. JK184 exhibits antiproliferation activities in a wide range of cancer cell lines with abnormally activated Hh signaling (GI50= 3-21 nM) as well as in human xenografts in vivo [1]. JK184 is shown to modulate Hedgehog target gene expression by depolymerizing microtubules [2].
Chemical Properties
Cas No.: 315703-52-7
M. Wt.: 350.44
Formula: C19H18N4OS
Purity: ≥98%
Synonym: Hh Signaling Antagonist VII
Chemical Name: N-(4-Ethoxyphenyl)-4-(2-methylimidazo[1,2-a]pyridin-3-y l)-2-thiazolamine
Appearance: Beige solid
Solubility: Soluble to 100 mM in DMSO and to 25 mM in ethanol